Search research articles
Contact Us
Filters
Showing results (81-90 of 210) with videos related to
Page
of 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2020
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer
Biagio Ricciuti, Gonzalo Recondo, Liam F Spurr, et al.
Science Translational Medicine
|
February 4, 2026
Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models
Hai-Cheng Huang, Qing Deng, Lei Guo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2016
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M Awad, Geoffrey R Oxnard, David M Jackman, et al.
JTO Clinical and Research Reports
|
April 2, 2025
PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief Report
Elio Adib, Amin H Nassar, Elias Bou Farhat, et al.
JCO Precision Oncology
|
September 24, 2025
Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas
Jessica S Ross, Rohit Thummalapalli, Kristine Lacuna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer
Ibiayi Dagogo-Jack, Pablo Martinez, Beow Y Yeap, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2025
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer
Xinan Wang, Biagio Ricciuti, Arielle Elkrief, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 19, 2017
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
Mark M Awad, Quincy S-C Chu, Leena Gandhi, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2022
Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade
Umair Mahmood, Mai Anh Huynh, Joseph H Killoran, et al.
Cancer Discovery
|
October 4, 2016
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Magda Bahcall, Taebo Sim, Cloud P Paweletz, et al.
Page
of 21
Search research articles
Search
Showing results (81-90 of 210) with videos related to
Sort By:
Page
of 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2020
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer
Biagio Ricciuti, Gonzalo Recondo, Liam F Spurr, et al.
Science Translational Medicine
|
February 4, 2026
Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models
Hai-Cheng Huang, Qing Deng, Lei Guo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2016
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M Awad, Geoffrey R Oxnard, David M Jackman, et al.
JTO Clinical and Research Reports
|
April 2, 2025
PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief Report
Elio Adib, Amin H Nassar, Elias Bou Farhat, et al.
JCO Precision Oncology
|
September 24, 2025
Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas
Jessica S Ross, Rohit Thummalapalli, Kristine Lacuna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer
Ibiayi Dagogo-Jack, Pablo Martinez, Beow Y Yeap, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2025
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer
Xinan Wang, Biagio Ricciuti, Arielle Elkrief, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 19, 2017
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
Mark M Awad, Quincy S-C Chu, Leena Gandhi, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2022
Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade
Umair Mahmood, Mai Anh Huynh, Joseph H Killoran, et al.
Cancer Discovery
|
October 4, 2016
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Magda Bahcall, Taebo Sim, Cloud P Paweletz, et al.
Page
of 21